Reading time: ~2 min · Part of the free certification in peptide science
GHRH analogs act on the GHRH receptor in the pituitary, mimicking the stimulatory hypothalamic signal. They differ mainly in their pharmacokinetics:
- Sermorelin: corresponds to the active fragment GHRH(1-29). It is short-acting, with a profile close to physiological.
- CJC-1295: a long-acting version. The form without DAC (sometimes called modified GRF 1-29) incorporates substitutions that make it resistant to DPP-4; the form with DAC (Drug Affinity Complex) adds albumin binding that drastically extends its duration.
- Tesamorelin: a stabilized GHRH analog with formal clinical development in a specific fat distribution indication.
Choosing a GHRH analog revolves around a pharmacokinetic trade-off: longer duration simplifies administration but moves away from the physiological pulsatile pattern; shorter action respects it better but requires greater frequency.
Catalogue compounds mentioned in this lesson
Take the module 5 quiz and earn your certificate
The certification is free: read the lessons, pass each module quiz and the final exam, and download your PDF certificate with a verifiable ID.
Go to the quiz →Educational content for scientific purposes. It distinguishes preclinical from clinical evidence and is not medical advice, diagnosis or a recommendation for use. NeoPeptidos products are sold labelled for research use only (RUO).